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Aim: Experimental and clinical studies showed that bikunin, a Kunitz-type protease inhibitor, found in urine and amniotic fluid has 
a role in spread of tumor cells by providing a significant reduction in the levels of urokinase-type plasminogen activator (uPA) and 
its specific receptor urokinase-type plasminogen activator receptor (uPAR). The aim of this study was to investigate expression 
of bikunin at the mRNA level and screen for mutations in exon sequence in renal cell carcinoma (RCC) tissues. Materials and 
Methods: Total RNA and DNA were extracted from paired normal and tumor tissues of total 50 RCC (11 papillary, 8 chromophobe, 
26 clear cell, and 5 other types) patients (23 females, mean age: 53.55 ± 14.17; 27 males mean age: 62.1 ± 7.92). Bikunin mRNA 
levels were detected using semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR). Mutational screening 
was performed by using single strand conformation polymorphism (SSCP) method and nucleotide sequence analysis. Results: There 
was a statistically significant decrease in the 25 (50%) of tumor tissues comparing to normal tissues in terms of mRNA levels 
of bikunin (Wilcoxon signed rank test, p = 0.0337). According to the classification based on subtypes of RCC; clear cell RCC 
samples displayed a reduced gene expression (p = 0.0148). Additionally, the patients with the age above 50 had low bikunin expres-
sion. The SNP rs80057939 spanning 4th exon of bikunin was detected in 13 tumor tissues. However, it was not statistically sig-
nificant (p > 0.05). Conclusion: Decreased bikunin mRNA level in renal cells might be associated with poor prognosis of renal 
carcinoma. Therefore, gene constructs or exogenous administration of bikunin might be a potential adjuvant therapy for RCC 
treatment.
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Kidney neoplasms account for approximately 2% 
of all cancers [1], and clear cell renal cell carcinoma 
(RCC), papillary RCC, oncocytoma, and chromophobe 
RCC are the most frequent types of renal cancers [2]. 
Several genes have been associated with renal tumor 
generation, progression, proliferation, invasion, and 
metastasis by using mutational screening, gene and 
protein expression analyses [1].
Bikunin, a Kunitz-type protease inhibitor, is found 
in human amniotic fluid, urine, serum [3], and also 
known as urinary trypsin inhibitor (uTi), miraclid, min-
gin, serpin, human inhibitor 30 (HI-30), urinastatin, 
ulinastatin [4]. Bikunin is mainly expressed in liver 
tissue, but also expressed at lower concentrations 
in pancreas, kidney, lung, intestine, stomach, skin, 
gallbladder, cerebrum, cerebellum, testis, brain, mast 
cells, and colon suggesting different physiological 
roles of bikunin [5–11].
Protease inhibitors that contain Kunitz domain 
function to obstruct protease activities throughout 
homeostasis, tissue injury, inflammation, and cancer 
formation and progression [12]. The balance between 
proteases and protease inhibitors is critical in invasion 
and metastasis of tumor cells [13]. The expression level 
of bikunin alters in case of cancer, infection, tissue in-
jury, kidney disease, vascular disease, and diabetes [4]. 
The concentration of bikunin protein in plasma and urine 
changes in the same conditions, as well [4].
Bikunin suppresses invasion and metastasis capa-
bility of tumor in many cell lines by inhibiting cell-asso-
ciated plasmin activity as well as by inhibiting uPA-uPAR 
gene and protein expression levels by suppression 
of TGF-β1-dependent ERK1/2 activation [14–16]. Bi-
kunin has a proven anti-invasive and anti-metastatic 
effect in several types of malignant cells [17, 18].
In this study, we aimed to determine the possible 
association between bikunin and RCC pathogenesis 
by monitoring the expression level and sequence 
analysis of bikunin in order to investigate the possible 
role of bikunin in RCC.
MATERIALS AND METHODS
Normal and tumor tissue specimens. Fifty paired 
tumor and normal samples of RCC (11 papillary, 8 chro-
mophobe, 26 clear cell, and 5 other subtypes) patients 
(23 females, mean age: 53.55 ± 14.17; 27 males, mean 
age: 62.1 ± 7.92) were obtained by primary surgery 
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at the Department of Urology, Faculty of Medicine, 
University of Gaziantep. Informed consent was taken 
from all participants. The obtained tissues were placed 
into liquid nitrogen immediately after the surgery and 
stored at −80 °C until the DNA and RNA were extracted. 
This study was approved by the local ethical committee, 
in accordance with the declaration of Helsinki.
DNA & RNA extraction. DNA samples and RNA ex-
traction was carried out upon confirmation by histopatho-
logical analysis. DNA samples were obtained by using 
extraction kits (for DNA: Qiagen, QIAmp DNA Mini Kit, 
Catalog No. 51306; for RNA: Qiagen RNA Isolation Kit, 
Catalog No. 74104, Hilden, Germany) according to the in-
structions of the manufacturer. Quantification of DNA and 
RNA concentrations were performed by  using spectro-
photometer (NanoDrop, ND-1000, USA).
Semi-quantitative reverse transcription PCR 
analysis. cDNAs were synthesized from RNA samples 
by using AB High Capacity RNA-to-cDNA kit (Catalog 
No. 4387951, USA) according to manufacturer’s instruc-
tions. cDNAs were amplified by the expression primers 
seen in Table 1. Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was used as a housekeeping gene 
for the normalization of bikunin gene expression data. 
The numbers of cycles for bikunin and GAPDH amplifi-
cations were 30 and 25, respectively. Expression altera-
tions were demonstrated by agarose gel electrophoresis 
(2%) in the presence of 0.5  g / mL of ethi dium bromide. 
The  image of the agarose gel was captured and quanti-
tated by ImageJ software (v1.46r).
Table 1. The primers used for PCR amplification
Primers Pr imer sequences
 Expected 
size 
of PCR 
products 
(bp)
Anne-
aling 
tempe-
ratures 
(°C)
BKN1-F (AMBP-7) CAGAAATCTGTCCTCTGATGC 307 54.7
BKN1-R (AMBP-7) AACACCTGCCTTTTCACCC
BKN2-F (AMBP-8) ACACTTGGTCAGTGCTGCTG 277 58.7
BKN2-R (AMBP-8) ATTCGCAGGTGGTTTACTGG
BKN3-F (AMBP-9) ATGCCTCTCTCCACTCCACA 255 53.6
BKN3-R (AMBP-9) TCTCCACCTCGACTCCAAC
BKN4-F (AMBP-10) TGTGTCCACAGGTGATGAGG 209 61.3
BKN4-R (AMBP-10) TCCGCCACCCTGTTAGTTAC
BKNexFw CTGCAATCTCCCCATAGTC 230 58.7
BKNexRv ATCCTCTGACTTGCAGACC
GAPDHFw
GAPDHRv
GGTCCACCACCCTGTTGCTGT
AGACCACAGTCGATGCCATCAC
456 59.4
PCR analysis. Primers were designed by using 
Primer-BLAST (see Table 1). PCR amplifications were 
performed in 20 μl master mixture containing 2 μl ge-
nomic DNA, 20 pmole each of primers, 10× buffer, 
2 mM each of nucleotides (dATP, dCTP, dGTP, dTTP) 
and 0.5 unit of Taq DNA polymerase. PCR conditions 
were as follows: initial denaturation at 95 °C for 5 min, 
35 cycles of denaturation at 95 °C for 45 s, anne aling 
at the temperatures seen in Table 1 for 45 s, and 
elongation at 72 °C for 45 s. A final extension step 
was applied at 72 °C for 5 min. PCR experiments were 
carried out by AB Thermal Cycler. PCR products were 
electrophoresed in 2.0% agarose gel.
Single strand conformation polymorphism 
(SSCP) analysis & sequencing. 7–10 μl loading dye 
(95% formamide, 20 mM EDTA, 0.05% xylene cyanol) 
was added into PCR tubes containing 3 μl PCR pro-
ducts. Samples were denatured at 95 °C for 5 min and 
were put on ice to prevent renaturation, and electro-
phoresed on 7% polyacrylamide gel (49:1 Acrylamide : 
 Bisacrylamide). To visualize DNA bands, silver nitrate 
staining was used.
In order to confirm SSCP results, the fragments 
which showed different mobility were excised from 
the gel and analyzed by ABI 3130 nucleotide sequen-
cer. The obtained sequence was compared with 
the reference assembly in the NCBI database (Acces-
sion number: NT_008470.19).
Statistical analysis. Prior to the statistical evalu-
ation of expression results, D’Agostino & Pearson 
omnibus normality test, Shapiro — Wilk normality test, 
and Kolmogorov — Smirnov test were used to examine 
the normality of the variables’ distributions. Subsequently, 
the expression data was assessed by Wilcoxon signed 
rank test. The sequencing results were evaluated by t-test.
The postoperative period was measured from 
the surgery to the death or last follow-up. In order to es-
timate the cumulative survival probabilities among RCC 
patients, the Kaplan — Meier curve was used. The risk 
ratio of contributions of covariates such as expression 
alterations, age, gender, tumor size, and metastatic 
state were assessed by a Cox proportional hazards 
model. A 2-tailed value p < 0.05 was considered sta-
tistically significant in all of the statistical tests. The 
statistical tests were made by  using Graphpad Prism 
(v.6.02) and SPSS (v.16) softwares.
RESULTS
Gene expression analysis. The median value 
of the bikunin mRNA to GAPDH mRNA ratio in normal 
and tumor samples was calculated as 1.072 and the ra-
tio higher than 1.072 was defined as overexpression. 
Twenty-five of total 50 RCC specimens had lower bi-
kunin gene expression comparing to normals. The dis-
tributions of variables’ were significant (D’Agostino & 
Pearson omnibus normality test, Shapiro — Wilk nor-
mality test and Kolmogorov — Smirnov test; p < 0.05). 
The bikunin mRNA levels measured in tumor tissue were 
significantly lower than normal tissue of patients with 
RCC (Fig. 1, Table 2) (p = 0.0337). When the specimens 
were subdivided according to the subtypes of RCC, 
the clear cell type of RCC displayed the significantly 
low expression of bikunin (p = 0.0021). Furthermore, 
in terms of clinicopathologic parameters, only age 
is observed as a significant covariate in bikunin expres-
sion. The mRNA expression level of bikunin of tumor 
samples that belong to patients above 50 years old was 
significantly lower than normal samples (p = 0.0147). 
However, metastasis-negative tumors were significantly 
low expressors of bikunin (p = 0.0388). No significant 
difference in clinical stage, pathological stage, or tumor 
size was detected for patient group (p > 0.05).
There was no significant difference in the survival 
rates of patients with the low and high expression 
of bikunin (p > 0.05) (Fig. 2). Cox proportional hazards 
model showed that low level of bikunin expression 
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(p = 0.028) and age above 50 (p = 0.046) were sig-
nificant risk factors affecting overall survival (Table 3).
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Fig. 1. Comparison of bikunin expression levels in tumor and nor-
mal samples. Twenty-five of total were low expressers of bikunin
Table 2. The relationship between clinical parameters and bikunin expres-
sion level
Bikunin mRNA expression
Characteristics Total number High Low p value
Age (years)
< 50 10 5 5 NS
> 50 40 25 15 0.0147
Subtype of RCC
Classic RCC 10 3 7 0.0488
Papillary RCC 11 8 3 NS
Chromophobe RCC 8 5 3 NS
Clear cell RCC 16 7 9 0.0021
Other 5 2 3 NS
Total RCC 50 25 25 0.0337
Clinical Stage
T1 1 0 1 NS
T1a 5 4 1 NS
T1b 17 9 8 NS
T2 1 1 0 NS
T2a 14 7 7 NS
T2b 8 5 3 NS
T3 3 3 0 NS
Unknown 1 1 0 NS
Pathological Stage
T1 13 10 3 NS
T1a 2 1 1 NS
T2 18 11 7 NS
T3 2 1 1 NS
T3a 3 1 2 NS
Unknown 12 6 6 NS
Tumor size (cm)
< 5 13 6 7 NS
5–10 28 16 12 NS
> 10 9 9 0 NS
Metastasis
Positive 14 7 7 NS
Negative 36 18 18 0.0388
Note: NS — not significant.
Table 3. Analysis the effects of risk factors on overall survival by Cox pro-
portional hazard model
P Hazard 95,0% CI for HazardLower Upper Wald
Expression Level 0.028 0.107 0.015 0.782 4.853
Age 0.046 1.039 1.001 1.079 3.966
Gender 0.728 1.181 0.462 3.019 0.121
Metastasis 0.316 1.590 0.643 3.932 1.007
Tumor size 0.332 1.060 0.942 1.193 0.332
Note: 95% CI — 95% confidence interval.
SSCP and nucleotide sequence analysis. As a re-
sult of SSCP and sequence analyses, 13 of 50 kidney 
carcinoma samples (26%) displayed A > G substitution 
which was formerly identified as rs80057939 (p = 0.069) 
(Fig. 3). rs80057939 is located on the 3’-UTR of bikunin 
gene and was the only single nucleotide polymorphism 
(SNP) detected in our samples.
Fig. 2. Impact of expression level of bikunin on cumulative sur-
vival was assessed via Kaplan — Meier method. No significant 
relationship was observed (p > 0.05)
Fig. 3. Gel image of SSCP of exon 4. The band indicated by the ar-
row was excised from the gel and subjected to sequence analysis. 
G>A substitution (rs80057939) was observed in 13 of 50 (26%) 
tumor samples (p > 0.05)
DISCUSSION
RCC, with different histopathological features, 
genetic expression and clinical behavior, is a hetero-
geneous disease with many subtypes [2, 19]. The most 
common subtypes of RCC are clear cell, papillary, and 
chromophobe comprising approximately 70 to 80%, 
14 to 17%, and 4 to 8% of all, respectively [20]. Seve-
ral numbers of immunomarkers have been utilized 
for early detection and prognosis of renal tumors. 
However, most of them are not specific despite being 
sensitive. PAX2, PAX8, CD10, and RCC marker are 
the most preferred markers for diagnosis of RCC [20].
In recent years, experimental and clinical results 
showed that bikunin takes part in many biological 
processes [21–23]. Many proteolytic enzymes such 
as uPA [24–26], cathepsin [27] and various matrix me-
talloproteins (MMPs) [28–31] play crucial role in tumor 
metastasis. During proliferation of tumor cells, control 
mechanism of proteases are lost [32]. Bikunin exhibits 
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anti-metastatic functions in animals and humans. Several 
bikunin-regulated genes were identified and of these PI3K 
is considered to be a critical bikunin target gene [33]. 
Kobayashi et al. demonstrated that in HRA cells after 
TGF-β1 treatment Akt is phosphorylated and that reduced 
PI3K expression due to inhibition of PI3K activity prevent 
the uPA up-regulation and invasion in HRA cell line [34].
In a study analyzing 13 different tumor tissues, in terms 
of expression levels of the genes of inter-α-inhibitor fa-
mily, bikunin was reported to be expressed abundantly 
in all of the tumor tissues except the kidney tissue which 
displayed bikunin down-regulation in a ratio of 90% [35]. 
This interesting data can also give rise to an important 
point that is mostly unclear: the reason for abundant 
expression of bikunin especially specific to kidney tissue. 
One of the possible explanations may be the tendency 
for stone formation in the urine that triggers expression 
of bikunin as a calcium chelator to struggle with calcium 
oxalate (CaOx) kidney stones in a continual manner [36]. 
However, the functions and biological significance of bi-
kunin remains to be established.
The experiments measured the protein level of bikunin 
in urine of kidney cancer patients revealed that the amount 
of bikunin in urine varies in consistent with the number 
of cancer cells [37]. However, there is no such a detailed 
study at the molecular level performed with RCC patients.
To demonstrate the effect of bikunin expression 
at the mRNA level in RCC, we performed semi-quan-
titative RT-PCR and sequencing experiments. The re-
lationship between low bikunin expression and poor 
prognosis of RCC was independent of gender, tumor 
size, pathological stage or clinical stage of patients 
(p > 0.05) (see Table 2). Interestingly, bikunin down-
regulation was common among metastasis-negative 
patients (p = 0.0388) (see Table 2). The small number 
of our patient group may give rise to this result. Fur-
ther studies with larger groups are required to clarify 
the effect of metastatic state in RCC.
In a Cox proportional hazards model of the risk fac-
tors, low bikunin expression was an independent factor 
for overall survival of RCC patients. Older age (> 50 years) 
was strongly associated with higher risk of RCC develop-
ment and decreased bikunin mRNA expression.
To investigate the probable mutations of bikunin, 
the 4 exonic regions were examined by SSCP and 
nucleotide sequence analysis. Only 4th exon of bikunin 
[10th exon of AMBP (Alpha1-microglobulin/bikunin 
precursor)] showed a formerly identified polymorphism 
rs80057939. A > G substitution was observed in 13 tu-
mor tissues (26%) of RCC patients. However, it was not 
statistically significant (p > 0.05). There is no significant 
relationship between RCC pathogenesis and nucleotide 
sequence of bikunin suggesting that somatic mutations 
may not be a cause of bikunin inactivation.
Cancer remains a significant health burden worldwide. 
As a potential approach to the RCC treatment, gene 
constructs or exogenous administration of bikunin might 
be of clinical use due to possessing significant clinical im-
pact, low production cost and minimum side effects [38]. 
As it is not antigenic to human, it has been suggested 
as a drug for patients with tumor [21], cerebral ische-
mia [39], and severe acute pancreatitis [40]. Therefore, 
a drug such as bikunin that manipulate signal transduction 
on the plasminogen activator (PA) system in malignant 
cells may offer a new potential approach to anti-cancer 
therapy. Bikunin treatment may be beneficial as an ad-
juvant therapy against metastasis in patients with RCC.
Additionally, a recent study indicated the elevated 
urinary α1-microglobulin level is associated with a range 
of important clinical outcomes [41]. Alpha1-microglobu-
lin was a urinary biomarker associated with incident renal 
cancer [41]. However, in this report the molecular cause 
of increased α1-microglobulin level was not discussed 
in detail. As known, alpha1-microglobulin and bikunin are 
products of a cleavage of one polypeptide chain [42]. 
They have different functions, however. The study 
of O’Seaghdha and coworkers [41] is one of the few 
studies indicating the role of α1-microglobulin in cancer. 
Interestingly, Medetognon-Benissan and coworkers 
observed a positive correlation between the urinary 
excretion of bikunin and α1-microglobulin in healthy 
controls, while there was no such correlation in CaOx 
stone  formers [43]. However, these two studies were per-
formed measuring the protein level. The inconsistency 
between the results of our study and O’Seaghdha et al. 
requires further protein analysis. The molecular mecha-
nisms regulating the bikunin expression, the up- and 
down-stream events were not identified, as well.
According to our data, bikunin is a good marker 
for poorer prognosis in patients with RCC, especially 
in clear cell subtype. Expression of bikunin gene is sig-
nificantly decreased among patients who are older than 
fifty years (see Table 2) and the risk for RCC is higher 
among the same group of patients, as well (see Table 3). 
Therefore, bikunin mRNA expression in RCC might 
be used as a prognostic marker. Howe ver, these are 
preliminary results and need to be verified by determi-
nation of protein levels in larger populations.
In conclusion, a statistically significant relationship 
was established between the reduced level of bikunin 
and RCC pathogenesis compared to normal kidney tis-
sue samples. To date, the regulation of bikunin expres-
sion, the downstream events of bikunin signaling, and 
all of the genes that response to bikunin remain mostly 
unclear. Future studies investigating the regulation of bi-
kunin improve our understanding of the biological signifi-
cance of bikunin in healthy and cancer tissues, clearly.
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